^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Hematological Malignancies

    Related cancers:
    18h
    BGB-3111-215t: Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment (clinicaltrials.gov)
    P2, N=90, Active, not recruiting, BeiGene | Trial completion date: Oct 2025 --> Dec 2025 | Trial primary completion date: Oct 2025 --> Dec 2025
    Trial completion date • Trial primary completion date
    |
    Imbruvica (ibrutinib) • Brukinsa (zanubrutinib) • Calquence (acalabrutinib)
    18h
    INCB 84344-102: Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors (clinicaltrials.gov)
    P1/2, N=70, Recruiting, Incyte Biosciences International Sàrl | Trial completion date: Jan 2026 --> Feb 2028 | Trial primary completion date: Jan 2026 --> Feb 2028
    Trial completion date • Trial primary completion date
    |
    FLT3 (Fms-related tyrosine kinase 3) • ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • RET (Ret Proto-Oncogene) • FGFR (Fibroblast Growth Factor Receptor) • BLM (BLM RecQ Like Helicase)
    |
    EGFR mutation • KIT mutation • FGFR mutation • RET mutation
    |
    Iclusig (ponatinib)
    18h
    ALICIA(BY): Observ Prosp Study of Acalabrutinib in CLL Therapy in Real Clinical Practice in Belarus (clinicaltrials.gov)
    P=N/A, N=50, Not yet recruiting, AstraZeneca
    New trial
    |
    Calquence (acalabrutinib)
    19h
    Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome (clinicaltrials.gov)
    P1/2, N=80, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2027
    Trial completion date • Trial primary completion date
    |
    cytarabine • Vanflyta (quizartinib) • idarubicin hydrochloride • cladribine • Starasid (cytarabine ocfosfate)
    21h
    Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant (clinicaltrials.gov)
    P1/2, N=16, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2027
    Trial completion date • Trial primary completion date
    |
    cyclophosphamide • fludarabine IV
    21h
    Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P2, N=18, Recruiting, University of Washington | Not yet recruiting --> Recruiting
    Enrollment open
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • daunorubicin • Epkinly (epcoritamab-bysp) • Truxima (rituximab-abbs) • Mabtas (rituximab biosimilar)
    22h
    Diet and Cognitive Training in Hematologic Cancer Survivors (clinicaltrials.gov)
    P=N/A, N=80, Recruiting, University of Alabama at Birmingham | Trial completion date: Apr 2026 --> Apr 2027 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    23h
    NCI-2020-09704: Low-Dose Selinexor and Choline Salicylate for Non-Hodgkin or Hodgkin Lymphoma, Histiocytic/Dendritic Cell Neoplasm, or Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=22, Active, not recruiting, Mayo Clinic | Trial completion date: Aug 2027 --> Jun 2026
    Trial completion date
    |
    Xpovio (selinexor)
    1d
    MUKEight: Phase II Randomised Trial of Cyclophosphamide & Dexamethasone in Combination With Ixazomib in Relapsed or Refractory Multiple Myeloma. (clinicaltrials.gov)
    P2, N=112, Completed, University of Leeds | Unknown status --> Completed | Trial completion date: Jan 2021 --> Jan 2025
    Trial completion • Trial completion date
    |
    lenalidomide • bortezomib • cyclophosphamide • Ninlaro (ixazomib) • thalidomide
    1d
    CARTIFAN-1: A Study of LCAR-B38M CAR-T Cells, a Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Chinese Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P2, N=123, Terminated, Nanjing Legend Biotech Co. | Active, not recruiting --> Terminated; The study was terminated early due to a strategic realignment of the sponsor's business plan, not related to safety, efficacy, or data integrity concerns.
    Trial termination • IO biomarker
    |
    Carvykti (ciltacabtagene autoleucel)
    1d
    Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia (clinicaltrials.gov)
    P2, N=151, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2027
    Trial completion date • Trial primary completion date
    |
    RARA (Retinoic Acid Receptor Alpha) • PML (Promyelocytic Leukemia)
    |
    Mylotarg (gemtuzumab ozogamicin) • Vesanoid (tretinoin) • arsenic trioxide
    1d
    DALY II Japan/MB-CART2019.1 for DLBCL (clinicaltrials.gov)
    P2, N=31, Not yet recruiting, Miltenyi Biomedicine GmbH
    New P2 trial
    |
    zamtocabtagene autoleucel (MB-CART2019.1)